Trial ID or NCT#



recruiting iconRECRUITING


The main purpose of this study is to evaluate the efficacy and safety of the study drug known as Galcanezumab in participants with episodic cluster headaches.

Official Title

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients With Episodic Cluster Headache

Eligibility Criteria

Ages Eligible for Study: 18 Years to 65 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Nada Hindiyeh, MD
Nada Hindiyeh, MD
Headache specialist
Clinical Associate Professor, Neurology & Neurological Sciences

Contact us to find out if this trial is right for you.


(650) 723-5184